Goldman Sachs’s Unicycive Therapeutics UNCY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.23M Buy
262,767
+117,463
+81% +$609K ﹤0.01% 5076
2026
Q2
$681K Buy
145,304
+118,211
+436% +$872K ﹤0.01% 5497
2026
Q1
$178K Buy
+27,093
New +$178K ﹤0.01% 6112
2025
Q4
– Sell
-45,200
Closed -$197K – 6837
2025
Q3
$197K Buy
+45,200
New +$197K ﹤0.01% 5958
2025
Q2
– Sell
-7,348
Closed -$42.2K – 6436
2025
Q1
$42.2K Sell
7,348
-13
-0.2% -$79 ﹤0.01% 5903
2024
Q4
$58.5K Sell
7,361
-1,981
-21% -$11K ﹤0.01% 5837
2024
Q3
$38.1K Buy
9,342
+7
+0.1% +$28 ﹤0.01% 5648
2024
Q2
$46.8K Buy
9,335
+1
+0% +$10 ﹤0.01% 5475
2024
Q1
$129K Hold
9,334
– – ﹤0.01% 5196
2023
Q4
$81K Buy
9,334
+11
+0.1% +$72 ﹤0.01% 5325
2023
Q3
$80.2K Sell
9,323
-270
-3% -$2.53K ﹤0.01% 5218
2023
Q2
$123K Buy
+9,593
New +$150K ﹤0.01% 5320

Other funds holding UNCY

Goldman Sachs's UNCY Position: Q3 2026 in Review

Goldman Sachs increased its Unicycive Therapeutics (UNCY) stake by 81% in Q3 2026, buying an estimated $609K and bringing the position to 262,767 shares worth $1.23M. The position accounts for ﹤0.01% of the portfolio, ranked #5076.

Goldman Sachs first reported a position in UNCY in Q2 2023 and has held it in 12 quarters since. 95 funds tracked by Wall St. Rank hold UNCY as of Q3 2026.

  • Goldman Sachs held 262,767 shares of Unicycive Therapeutics worth $1.23M as of Q3 2026.
  • Goldman Sachs bought 117,463 Unicycive Therapeutics shares in Q3 2026, an estimated $609K.
  • Unicycive Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q3 2026, its #5076 holding.
  • Goldman Sachs first reported a position in Unicycive Therapeutics in Q2 2023 and has held it in 12 quarters since.
  • 95 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q3 2026.

Based on Goldman Sachs's 13F filing for Q3 2026, filed 16 Nov 2026.